Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia

Loading...
Thumbnail Image

Persistent link to this item

Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia

Published Date

2010-04-21

Publisher

Type

Presentation

Abstract

Acute myeloid leukemia (AML) is the most common and most deadly type of leukemia in adults, affecting approximately 3 people per 100,000. AML is typically treated with a cocktail of chemotherapeutic drugs, most often involving the pharmaceutical agent cytosinearabinoside (Ara-C). Treatment with Ara-C will almost always cause remission in AML patients. However, developed resistance to Ara-C becomes a problem for many patients suffering from the disease, and many relapse within a few years of remission. We are using an in vitro system to model the Ara-C resistance in AML cell lines.

Description

Additional contributors: Susan K. Rathe; David A. Largaespada (faculty mentor)

Related to

Replaces

License

Series/Report Number

Funding information

Funding for this project was provided by The Leukemia and Lymphoma Society (grant 7019-04).

Isbn identifier

Doi identifier

Previously Published Citation

Suggested citation

Ellingson, Alexandra M.. (2010). Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/62360.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.